← Back to Clinical Trials
Recruiting NCT06214611

NCT06214611 Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06214611
Status Recruiting
Phase
Sponsor University Hospital, Essen
Condition Head and Neck Cancer
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2023-11-15
Primary Completion 2024-12-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Adaptive Radiotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2023-11-15 with a primary completion date of 2024-12-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Adaptive radiotherapy (ART) includes image-guided radiotherapy (IGRT) and also offers further possibilities for plan adaptation. A particularly high benefit can be expected for patients in whom the clinical target volume (CTV) can show a significant change in shape from fraction to fraction due to anatomical deviations. The shape and position constancy of the CTV during the course of the series is examined in this trial. Dosimetric disadvantages of this type have not been reported so far. The aim of this study is to identify patients who benefit from ART at an early stage and to select them for this method, and then to continue to offer ART to this patient group. If a relevant reduction in the minimum planning target volume (PTV) margins with ART compared to IGRT is demonstrated in this study, patients could be treated with ART.

Eligibility Criteria

Inclusion Criteria: 1. ECOG 0-1 2. Histopathology confirmation 3. Compliance 4. Tumor in the head and neck region 5. Indication for radiotherapy Exclusion Criteria: 1\. Pregnancy

Contact & Investigator

Central Contact

Maja PD Dr. med. Guberina, PD Dr. med. (MD), specialist

✉ maja.guberina@uk-essen.de

📞 +492017232321

Frequently Asked Questions

Who can join the NCT06214611 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06214611 currently recruiting?

Yes, NCT06214611 is actively recruiting participants. Contact the research team at maja.guberina@uk-essen.de for enrollment information.

Where is the NCT06214611 trial being conducted?

This trial is being conducted at Essen, Germany.

Who is sponsoring the NCT06214611 clinical trial?

NCT06214611 is sponsored by University Hospital, Essen. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology